Oxular is a clinical-stage ophthalmic therapeutics company developing long-lasting targeted treatments for retinal diseases, delivering sustained-release drug formulations via suprachoroidal injection technology.
Oxular has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2014
Employees
11–50
Total Funding
$57.6M
2 rounds
Total raised $57.6M across 2 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series B
Date
March 1, 2021
Amount
$37M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| March 1, 2021 | Series B | $37M | — | Forbion |
| July 19, 2016 | Series A | $20.6M | — | V-Bio Ventures |
Mark Gaffney
Chief Executive Officer
Tom Cavanagh
Co-Founder
Ron Yamamoto
Co-Founder, Chief Scientific Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Allergan
Ophthalmic pharmaceutical company with portfolio in retinal disease treatment
Bausch Health Companies
Multi-specialty healthcare company with significant ophthalmic division
Aerie Pharmaceuticals
Ophthalmic pharmaceutical company focused on glaucoma and retinal conditions
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.